Then, we evaluated these findings in PAAD patients suggested that ITPR3 may be a robust factor in pancreatic cancer pathogenesis may sever as new drug targets and promising prognostic biomarkers for high pancreatic pathological cancer stage and poor disease outcome. This evidence concerns the gene ITPR3 and pancreatic neoplasm.